id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S17739 R75015 |
Zhu - Fluconazole, 2020 | Limb defects | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Fluconazole not specified or mixed dose | 0.98 [0.85;1.13] | 195/37,648 9,857/1,872,961 | 10,052 | 37,648 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17833 R75266 |
Berard - Fluconazole, 2019 | Musculoskeletal malformations | 1st trimester | nested case control | unexposed (general population or NOS) | Adjustment: Yes Fluconazole not specified or mixed dose | 1.16 [0.83;1.62] | 58/1,313 8,223/224,031 | 8,281 | 1,313 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17735 R74921 |
Molgaard-Nielsen - Fluconazole, 2013 | Limb defects | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Fluconazole not specified or mixed dose | 0.84 [0.57;1.23] | 27/7,352 4,143/968,236 | 4,170 | 7,352 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S17745 R75031 |
Jick - Fluconazole and Itraconazole (Oral), 1999 | Limb disorders (polydactyly, syndactyly, hip dislocation, talipes or others) | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.27 [0.27;5.99] C | 2/322 8/1,629 | 10 | 322 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 0.99 [0.87;1.12] | 22,513 | 46,635 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oral;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded